Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2023

Open Access 01-12-2023 | Insomnia | Study protocol

Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial

Authors: Xiangyang Gao, Junhua Li, Sanping Xu, Xueying Li, Xicheng Wang, Yongli Li, Yan Huang, Shaohui Liu, Qiang Zeng

Published in: Trials | Issue 1/2023

Login to get access

Abstract

Background

The treatment of insomnia, which is the most common sleep disorder, includes drug and behavioral treatment, but each treatment measure has its limitations. So new treatment method needs to be taken to improve the treatment effect. MN supplementation is a potential promising new method for the treatment of insomnia, resulting in a rising need for methodological research towards verifying its efficacy.

Methods/design

We describe a proposal for a multicenter, patient-assessor-blinded, randomized controlled trial with two parallel arms. A total of 400 chronic insomnia patients will be allocated 1:1 to the intervention group (treatment with oral NMN 320 mg/day) or control group (treatment with oral placebo). All subjects are clinical chronic insomnia patients who meet all inclusion criteria. All subjects are treated by taking NMN or placebo.
The primary outcome is the score on the Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes are the score on the Insomnia Severity Index (ISI) and Epworth Sleeping Scale (ESS), the total sleep time (TST), sleep efficiency (SE), sleep latency, and REM sleep latency to assess sleep quality changes.
Subjects are assessed at two time points: baseline and follow-up. The duration of the clinical trial is 60 days.

Discussion

This study will provide more evidence on the effects of NMN on improving sleep quality among patients with chronic insomnia. If proven effective, NMN supplement can be used as a new treatment for chronic insomnia in the future.

Trial registration

Chinese Clinical Trial Registry (chictr.org.cn) ChiCTR2200058001. Registered on 26 March 2022.
Literature
1.
Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387–94.CrossRefPubMed
2.
Avidan AY, Neubauer DN. Chronic Insomnia Disorder. Continuum (Minneap Minn). 2017;23(4 Sleep Neurology):1064–92.PubMed
3.
4.
5.
Chinese Society of Neurology SDS, Chinese Society of Neurology. Guideline for the evaluation and treatment of insomnia in Chinese adults(2017). Chin J Neurol. 2018;51(5):324–35.
6.
7.
Wickwire EM, Shaya FT, Scharf SM. Health economics of insomnia treatments: The return on investment for a good night’s sleep. Sleep Med Rev. 2016;30:72–82.CrossRefPubMed
8.
9.
Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report. Sleep. 2006;29(11):1415–9.CrossRefPubMed
10.
Hassinger AB, Bletnisky N, Dudekula R, et al. Selecting a pharmacotherapy regimen for patients with chronic insomnia. Expert Opin Pharmacother. 2020;21(9):1035–43.CrossRefPubMedPubMedCentral
11.
Cheung JMY, Bartlett DJ, Armour CL, et al. To Drug or Not to Drug: A Qualitative Study of Patients’ Decision-Making Processes for Managing Insomnia. Behav Sleep Med. 2018;16(1):1–26.CrossRefPubMed
12.
Buysse DJ, Germain A, Moul DE, et al. Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch Intern Med. 2011;171(10):887–95.CrossRefPubMedPubMedCentral
13.
14.
Trauer JM, Qian MY, Doyle JS, et al. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(3):191–204.CrossRefPubMed
15.
van Straten A, van der Zweerde T, Kleiboer A, et al. Cognitive and behavioral therapies in the treatment of insomnia: A meta-analysis. Sleep Med Rev. 2018;38:3–16.CrossRefPubMed
16.
Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020;26(4 Suppl):S76–84.PubMed
17.
Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.CrossRefPubMed
18.
Levine DC, Hong H, Weidemann BJ, et al. NAD(+) Controls Circadian Reprogramming through PER2 Nuclear Translocation to Counter Aging. Mol Cell. 2020;78(5):835-849 e7.CrossRefPubMedPubMedCentral
19.
20.
21.
Asher G, Gatfield D, Stratmann M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008;134(2):317–28.CrossRefPubMed
22.
Camacho-Pereira J, Tarrago MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127–39.CrossRefPubMedPubMedCentral
23.
24.
Satoh A, Brace CS, Rensing N, et al. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 2013;18(3):416–30.CrossRefPubMedPubMedCentral
25.
26.
Hong W, Mo F, Zhang Z, et al. Nicotinamide mononucleotide: a promising molecule for therapy of diverse diseases by targeting NAD+ metabolism. Front Cell Dev Biol. 2020;8:246.CrossRefPubMedPubMedCentral
27.
Uddin GM, Youngson NA, Doyle BM, et al. Nicotinamide mononucleotide (NMN) supplementation ameliorates the impact of maternal obesity in mice: comparison with exercise. Sci Rep. 2017;7(1):15063.CrossRefPubMedPubMedCentral
28.
Klimova N, Fearnow A, Long A, et al. NAD(+) precursor modulates post-ischemic mitochondrial fragmentation and reactive oxygen species generation via SIRT3 dependent mechanisms. Exp Neurol. 2020;325:113144.CrossRefPubMed
29.
Lundt S, Zhang N, Wang X, et al. The effect of NAMPT deletion in projection neurons on the function and structure of neuromuscular junction (NMJ) in mice. Sci Rep. 2020;10(1):99.CrossRefPubMedPubMedCentral
30.
Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–9.CrossRefPubMedPubMedCentral
31.
Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153–60.CrossRefPubMed
32.
Mollayeva T, Thurairajah P, Burton K, et al. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis[J]. Sleep Med Rev. 2016;25:52–73.CrossRefPubMed
33.
34.
Morin CM, Belleville G, Belanger L, et al. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601–8.CrossRefPubMedPubMedCentral
35.
Zhou QH, Wang HL, Zhou XL, et al. Efficacy and safety of suanzaoren decoction for chronic insomnia disorder in adults: study protocol for randomised, double-blind, double-dummy, placebo-controlled trial. BMJ Open. 2017;7(4):e014280.CrossRefPubMedPubMedCentral
36.
Wassertheil-Smoller S, Kim MY. Statistical analysis of clinical trials[J]. Semin Nucl Med. 2010;40(5):357–63.CrossRefPubMed
Metadata
Title
Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial
Authors
Xiangyang Gao
Junhua Li
Sanping Xu
Xueying Li
Xicheng Wang
Yongli Li
Yan Huang
Shaohui Liu
Qiang Zeng
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Insomnia
Published in
Trials / Issue 1/2023
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-023-07351-8

Other articles of this Issue 1/2023

Trials 1/2023 Go to the issue

Study protocol

Does closed-loop automated oxygen control reduce the duration of supplementary oxygen treatment and the amount of time spent in hyperoxia? A randomised controlled trial in ventilated infants born at or near term

Methodology

Re-analysis of ventilator-free days (VFD) in acute respiratory distress syndrome (ARDS) studies

Study protocol

Compression therapies for the treatment of venous leg ulcers: study protocol for a process evaluation in a randomised controlled trial, VenUS 6

Study protocol

Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial

Study protocol

Evaluating the efficacy and safety of acotiamide in patients with esophagogastric junction outflow obstruction: study protocol for an investigator-initiated, multi-center, randomized, double-blind, placebo-controlled phase II trial

Review

How do trial teams plan for retention during the design stage of the trial? A scoping review